The Auscann Group Holdings Ltd (ASX: AC8) share price had a day to remember on Tuesday. At one stage the medicinal cannabis company’s shares were up as much as 27% before finishing the day 23.5% higher at 52.5 cents.
Tag Archives: Price
Enforcing Canada’s new legal weed comes with a high price tag. The federal government will spend C$546 million ($426 million) over the next five years to implement its new cannabis laws, according to the latest budget forecast.
Folks in the cannabis industry fear that cultivation, production and retail regulations could drive up the price of weed just when consumers are able to buy in stores without a doctor’s recommendation.
Marijuana companies should be careful in overselling how much growth will be achieved or what the prospects will look like for the industry. There is a recent example that cannabis investors would be wise to review, and that’s what happened with Freshii Inc..
Ontario will try to sell legal pot for a price low enough to squash the black market. The government plans to establish a price for recreational marijuana that isn’t too high in order to eliminate illicit sales.
GW Pharmaceuticals Plc. is a biopharmaceutical company that discovers, develops, and commercializes cannabinoid prescription medicines. Since May 10, 2013, the stock price has climbed 1,033%.
Clinical-stage cannabinoid-based drug developer Zynerba Pharmaceuticals (NASDAQ:ZYNE) had been one of the strongest-performing pot stocks over the trailing year prior to the start of this past week.
The Creso Pharma Ltd (ASX: CPH) share price has been amongst the biggest movers on the market this morning. This morning the company revealed that it plans to expand into the Canadian market.
Few stocks have skyrocketed like Axim Biotechnologies. Last year, Axim ranked not only as the best marijuana stock in terms of overall performance, but also took the top spot among all biotech stocks.
In late May, MedReleaf priced its public offering at just over $7 per share. The marijuana stock IPO raised a whopping $75 million. Unfortunately, things didn’t work out as planned for pot investors or MedReleaf.
There is so much Canadian cannabis investment money right now that it is cascading down into the United States and Canadian investors are easily outbidding domestic acquirers.
Canopy Growth Corp.’s now down approximately 36% since my warning that the stock could be heading for a correction that would be triggered by the banned pesticides scandal.
The MMJ Phytotech Ltd share price has been a big mover in morning trade following the release of a positive announcement.
MyDx (OTCQB:MYDX) stock chart technical analysis for March 31, 2017.
MyDx (OTCQB:MYDX) Stock Chart Technical Analysis for March 24, 2017.
Canopy Growth Corporation’s generating eye-popping returns for investors. However, there are risks ahead that could rein in some investor optimism.
Marijuana prices are falling. Could marijuana stock prices drop soon, too?
Chris Blake, Senior Portfolio Manager, TD Wealth, explains what investors need to know before buying marijuana stocks.
Cannabis Science Inc (OTC:CBIS) — Stock Chart Technical Analysis for Jan. 23, 2017.
A new study has found that more than half of Americans will change their opinion on using marijuana depending on how tight or relaxed regulations are in their state.
On June 13, 2016, the Drug Policy Alliance issued a report that systematically assesses the first four months of New York’s medical marijuana program.
The amount dispensaries charge for an ounce of cannabis in Colorado varies radically from place to place.
STAMFORD, Conn., March 2, 2016 /Weed Wire/ — Cannabis Benchmarks®, a division of New Leaf Data Services, LLC, announced today the launch of its Professional Service in partnership with GlobalView.
STAMFORD, Conn., Feb. 2, 2016 /Weed Wire/ — Cannabis Benchmarks®, a division of New Leaf Data Services, LLC, announced today the launch of its Premium Weekly Report.
When recreational marijuana was legalized in the state of Washington, one of the biggest concerns was what pricing was going to look like for consumers.
Shareholders may buy into a company based on many factors, but paying off an old debt to one of the founding fathers is probably not one of them.
On a drug farm miles from anywhere in the central Andean mountains of Colombia, workers are digging up marijuana bushes and replacing them with avocados.
When the first recreational marijuana stores opened in Washington in July 2014, there was a consistent problem with supply—there simply was not enough. Close to eight months later the tables have turned in a drastic way.
Many 4th quarter updates have been released from the cannabis sector. Not surprising, most of these companies are worth very little.
Cannabis stocks traded poorly today. Fridays are generally plagued by poor volume and price weakness. Month ends exhibit similar characteristics.
Not you, not me, tax the man behind the tree. Unfortunately, discussions of tax policy sometimes never get beyond this point, but setting tax policy is like building infrastructure.
It is an ironic twist that seems appropriate for the marijuana business. Taxes collected from the retail sale of marijuana will be used to educate teens in Colorado about the dangers of drug use.
Broad market weakness returned today, wiping out all of yesterday’s gains and more. Uncertainty contributes to price confusion and volatility. This action indicates that investors are struggling with the current market and economic variables.
Taxes are like flies: no one really wants them around, but they play a vital role in their respective ecosystem. As summer flies by, Colorado officials are counting coffers and noticing an extreme shortfall in projected revenue from taxes on recreational cannabis.
It is the summer of 2014 and the legalization snowball continues to roll down the marijuana slope; it has been picking up speed for the past six months as Colorado and Washington have legalized the plant. Furthermore, since 1996, 23 states have changed their laws to allow medical marijuana.